UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway

Molecular and Cellular Biology, 2004-04, Vol.24 (8), p.3112-3124

2004

Volltextzugriff (PDF)

5‑(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Journal of medicinal chemistry, 2017-09, Vol.60 (17), p.7524-7538

2017

Volltextzugriff (PDF)

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (11), p.4500-4505

2005

Volltextzugriff (PDF)

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

Mini reviews in medicinal chemistry, 2004-03, Vol.4 (3), p.285-299

2004

Volltextzugriff (PDF)

NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (47), p.E4437-E4445

2013

Volltextzugriff (PDF)

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Clinical cancer research, 2005-07, Vol.11 (13), p.4941-4947

2005

Volltextzugriff (PDF)

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Journal of the American Chemical Society, 2010-05, Vol.132 (20), p.7043-7048

2010

Volltextzugriff (PDF)

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

Bioorganic & medicinal chemistry, 2010-10, Vol.18 (19), p.6977-6986

2010

Volltextzugriff (PDF)

The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588

Bioorganic & medicinal chemistry, 2013-06, Vol.21 (11), p.3231-3239

2013

Volltextzugriff (PDF)

AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

Cancer research (Chicago, Ill.), 2004-07, Vol.64 (14), p.4931-4941

2004

Volltextzugriff (PDF)

SH3GLB, a New Endophilin-Related Protein Family Featuring an SH3 Domain

Genomics (San Diego, Calif.), 2001-01, Vol.71 (2), p.222-234

2001

Volltextzugriff (PDF)

A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis

Journal of medicinal chemistry, 2016-01, Vol.59 (1), p.132-146

2016

Volltextzugriff (PDF)

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer cell, 2005-02, Vol.7 (2), p.129-141

2005

Volltextzugriff (PDF)

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

Nature chemical biology, 2006-02, Vol.2 (2), p.95-102

2006

Volltextzugriff (PDF)

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Blood, 2007-06, Vol.109 (11), p.5011-5015

2007

Volltextzugriff (PDF)

A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl

Journal of medicinal chemistry, 2010-08, Vol.53 (15), p.5439-5448

2010

Volltextzugriff (PDF)

Skp2 is Oncogenic and Overexpressed in Human Cancers

Proceedings of the National Academy of Sciences - PNAS, 2001-04, Vol.98 (9), p.5043-5048

2001

Volltextzugriff (PDF)

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Cancer research (Chicago, Ill.), 2000-04, Vol.60 (8), p.2178-2189

2000

Volltextzugriff (PDF)

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

Blood, 2006-08, Vol.108 (4), p.1328-1333

2006

Volltextzugriff (PDF)

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

BBA - Proteins and Proteomics, 2004-03, Vol.1697 (1-2), p.17-27

2004

Volltextzugriff (PDF)

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia

Blood, 2009-11, Vol.114 (22), p.510-510

2009

Volltextzugriff (PDF)

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

Journal of medicinal chemistry, 2000-06, Vol.43 (12), p.2310-2323

2000

Volltextzugriff (PDF)

Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors

Journal of medicinal chemistry, 2002-12, Vol.45 (26), p.5687-5693

2002

Volltextzugriff (PDF)

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Biochimica et biophysica acta, 2010-03, Vol.1804 (3), p.445-453

2010

Volltextzugriff (PDF)

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl

Blood, 2005-11, Vol.106 (11), p.3365-3365

2005

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(63)

Sprache

Englisch
(63)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(36)
Humans
(31)
Animals
(26)
Biological And Medical Sciences
(19)
Mice
(19)
Medical Sciences
(15)
Pharmacology & Pharmacy
(15)
Imatinib Mesylate
(14)
Pharmacology. Drug Treatments
(14)
Benzamides
(12)
Chemistry, Medicinal
(12)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(11)
Models, Molecular
(11)
Pyrimidines - Pharmacology
(10)
Antineoplastic Agents
(9)
Antineoplastic Agents - Pharmacology
(9)
Biochemistry & Molecular Biology
(9)
Female
(9)
Oncology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway

5‑(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588

AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

SH3GLB, a New Endophilin-Related Protein Family Featuring an SH3 Domain

A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl

Skp2 is Oncogenic and Overexpressed in Human Cancers

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl

Suchergebnisse filtern